DCR-MYC / Novo Nordisk - LARVOL DELTA

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - P1/2 | N=21 | Terminated | Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Phase classification: P1b/2 ➔ P1/2

Lipid Nanoparticle • Phase classification • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Chronic Microangiopathy Due to DCR-MYC, a Myc-Targeted Short Interfering RNA. (PubMed, Am J Kidney Dis) - "Another class of therapeutic agents that has been implicated in TMA is the vascular endothelial growth factor (VEGF) pathway inhibitors, including the anti-VEGF monoclonal antibody bevacizumab and the VEGF receptor tyrosine kinase inhibitor sunitinib. Determination of the cause of TMA in oncologic patients often presents a significant challenge because patients frequently receive multiple chemotherapeutic agents simultaneously and clinicopathologic features often demonstrate substantial overlap, regardless of cause. We present a case of TMA with predominantly chronic features in a 70-year-old patient being treated for adenoid cystic carcinoma of the breast with a single agent, a short interfering RNA targeted against Myc (DCR-MYC)."

Journal • Breast Cancer • Oncology • Solid Tumor